GLUE vs DNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 10, 2026

GLUE

51.0
AI Score
VS
GLUE Wins

DNA

42.9
AI Score

Investment Advisor Scores

GLUE

51score
Recommendation
HOLD

DNA

43score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric GLUE DNA Winner
Net Income -313,000 -84.84M DNA
Operating Income -315.28M -101.10M GLUE
ROE -0.1% -17.1% DNA
ROA -0.0% -12.2% DNA
Total Assets 1.12B 697.73M DNA
Cash 167.20M 45.18M DNA
Current Ratio 4.92 10.32 GLUE
Free Cash Flow -178.72M -130.61M GLUE

Relative Price Performance (Last 90 Days)

GLUE 1M: +4.2% · 3M: -34.9% DNA 1M: -12.8% · 3M: +41.6%

Current Technical Phase

GLUE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -13.2%), weak momentum, RSI 42

RSI (14): 42.1 · Price: $10.31

DNA

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 47.1 · Price: $10.25

Fundamentals Snapshot

Metric GLUE DNA
Market Cap — —
Forward P/E -5.8 -3.5
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 3.3% -0.1%
Gross Margin -0.9% 0.7%
Operating Margin 0.0% -1.6%
EPS -1.39 -4.24
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, GLUE is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.